Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Denali is focused on delivering biotherapeutics to the brain and has expanded its technology to target other regions of the body [2] - The company has seen significant maturation in both clinical and preclinical data, highlighting the effectiveness of using transferrin receptor technology for biotherapeutics [3] Company Overview - Denali was founded with the mission to develop biotherapeutics that can effectively access the brain [2] - The company is positioned in a competitive field, indicating a growing interest and activity in biotherapeutics targeting the central nervous system [3]